A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001
DF-006-1001
Phase 1 other active
Quick answer
A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-Human Study of Orally Administered DF-006 to Evaluate the Safety, Tolerability, and Pharmacokinetics After a Single Dose and Multiple Doses of Orally Administered DF-006 in Healthy Subjects (Part 1 and Part 2) and in Chronic Hepatitis B Patients (Part 3). Protocol Number Df-006-1001 for Chronic Hepatitis B is a Phase 1 program (other) at Ology Bioservices Ireland LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ology Bioservices Ireland LTD
- Indication
- Chronic Hepatitis B
- Phase
- Phase 1
- Modality
- other
- Status
- active